Soon after the discovery of the Myc gene (c-Myc), it became clear that Myc expression levels tightly correlate to cell proliferation. The entry in cell cycle of quiescent cells upon Myc enforced expression have been described in many models. Also, the downregulation or inactivation of Myc results in the impairment of cell cycle progression. Given the frequent deregulation of Myc oncogene in human cancer it is importat to dissect out the mechanisms underlying the role of Myc on cell cycle control. Several parallel mechanisms account for Myc-mediated stimulation of cell cycle. First, most of the critical positive cell cycle regulators are encoded by genes induced by Myc. These Myc target genes include Cdks, cyclins and E2F transcription factors. Apart from its direct effects on the transcription, Myc is able to hyperactivate cyclin/Cdk complexes through the induction of Cdk activating kinase (CAK) and Cdc25 phosphatases. Moreover, Myc antagonizes the activity of cell cycle inhibitors as p21 and p27 through different mechanisms. Thus, Myc is able to block p21 transcription or to induce Skp2, a protein involved in p27 degradation. Finally, Myc induces DNA replication by binding to replication origins and by upregulating genes encoding proteins required for replication initiation. Myc also regulates genes involved in the mitotic control. A promising approach to treat tumors with deregulated Myc is the synthetic lethality based on the inhibition of Cdks. Thus, the knowledge of the Mycdependent cell cycle regulatory mechanisms will help to discover new therapeutic approaches directed against malignancies with deregulated Myc.
as revealed in these and other studies, as well as the model where the effect is observed, are summarized in Table 1. The Table also shows the binding of Myc to the corresponding gene promoter by chromatin immunoprecipitation. The list includes pivotal cell cycle control genes as Cdks, cyclins and CIP/KIP proteins. Recent reports show that Myc functions as a general amplifier of already active genes but with low expression levels [95, 96] . However, the mRNA levels of some of the genes shown in Table 1 are dramatically increased upon activation of Myc in quiescent cells of different model systems, suggesting that Myc differentially upregulates at least some cell cycle control genes with respect to other genes.
The genome-wide gene expression studies show that Myc regulates a staggering number of genes, around 1000 in most models [85, [97] [98] [99] [100] [101] [102] . Thus, it is not surprising that many of these genes are related to cell cycle. In a gene expression profiling study in rat fibroblasts it has been shown that Myc overexpression regulated 37 out of 87 genes classified as belonging to the "cell cycle pathway" in the KEGG (Kyoto Encyclopedia of Genes and Genomes) [103] . In another study in mouse fibroblasts, about 300 genes have been identified as genes induced by serum in a Myc-dependent manner (i.e., not induced when Myc gene is silenced by RNA interference). Almost 80% of these genes have Myc bound to the promoter (i.e., in the interval ± 1kb from the transcription start site) [104] . This number of genes represents a small fraction (5.5% in the mentioned study) of all those bound by Myc, which is estimated to be the 10-20% of all genes by genome-wide studies [101, [105] [106] [107] [108] [109] [110] [111] . However, the affinity of Myc for these promoters is higher than the mean affinity for other Myc-targeted promoters. The ontology analysis revealed that only a minority of genes are involved in cell cycle control, whereas the majority of the genes are involved in other processes, including nucleotide biosynthesis, ribosome biogenesis, DNA replication and RNA control [104] . It is of note that many of the Myc-target genes are involved in de novo nucleotide biosynthesis, protein synthesis and energetic metabolism [97, [112] [113] [114] [115] . Given that the cell must duplicate its size along the cell cycle, synthesizing all cell components as well as all the nucleotides to be used for DNA replication, it is clear the importance of Myc in the biology of a cycling cell.
Transcription factors of the E2F family are critical for G1-S progression [7, 116] . E2F1, E2F2, and E2F3 are induced by ectopic Myc expression in quiescent cells (Table 1) and Myc fails to induce S-phase in E2F2 -/-or E2F3 -/-cells [117, 118] . Moreover, Myc binds to E2F1-3 promoters and the E-box in their promoters are required for full induction of E2F2 and E2F3 expression in response to mitogens [118, 119] (Table 1) . In contrast, E2F1 deficiency does not impair Myc-induced S-phase progression and Myc-induced tumorigenicity in vivo [117, 120] . In addition, E2F1 is negatively regulated by two microRNAs (miR-17 and miR-20a, from the miR-17-92 cluster) that are induced by Myc [121, 122] suggesting a regulatory mechanism through which Myc simultaneously activates E2F1 transcription and limits its translation. On the other hand, Myc promoter contains an E2F site which is important for Myc expression [123, 124] . However, the E2F site on Myc promoter does not seem to bind E2F proteins but a different transcription factor not yet identified [125] . Therefore, the precise mechanism of the Myc-E2F functional interaction awaits further study. Besides the induction of the mir-17-92 cluster described above, Myc activity has a major effect as a repressor of miRNAs that target critical cell cycle regulators. These miRNAs include let-7 family members, miR-15a/16-1, miR-26a or miR-34a. Key cell-cycle control factors targeted by let-7 miRNAs include Cdc25a, Cdk6, cyclin A, cyclin D1 D2 and D3 [126] [127] [128] . miR34a inhibit expression of cell-cycle regulators such as Cdk4, Cdk6, cyclin E2 and E2Fs, while miR-15a/16-1 regulates Cdk6, E2F3, cyclin D1 and D3; and miR-26a represses cyclin D2 and E2 (reviewed in [127, 129] ). Both induction and repression of specific miRNAs by Myc influences all levels of the cell cycle regulatory machinery and facilitates transit through the cell cycle.
Myc induces Cdks activity
Myc-induced cell proliferation is generally associated with an increase in Cdk2, Cdk4 and Cdk6 activities to regulate G1/S-phase progression [89, [130] [131] [132] (Fig. 1) . Importantly, Myc is able to augment the levels of active cyclin/Cdk complexes not only through the transactivation of the cyclin and/or Cdk genes but also by induction of Cdk activating kinase (CAK) or phosphatases (Cdc25 proteins) and/or repression of a Cdk inhibitory kinase (Wee1). These mechanisms are described below.
Cdk genes induction.
Among all Cdk genes, CDK4 seems to be the most clear Myc target gene, as it appears in most gene profiling studies ( Table 1 ). The upregulation of Cdk4 has been observed after Myc expression in several species (human and mouse) and cell types (endothelial cells, fibroblasts, B cells and epithelial cells), albeit at different degrees. The regulation of CDK4 by Myc seems to be direct, as suggested by the conservation of Myc binding sites in the Cdk4 promoter among different cell models and by the ability of Myc to activate the promoter in reporter assays [133] . Myc also binds to Cdk6 gene in ChIP-on-chip analysis in rat fibroblasts and Burkitt lymphoma cells (Daudi cells). Accordingly, Cdk6 mRNA is induced by Myc in these models, although no information about changes in Cdk6 protein expression have been reported [103, 108] . In addition, Myc binding sites to Cdk6 gene have been also identified in mouse embryonic stem cells [106, 107] and HeLa cells [134] .
The role of Myc in regulating Cdk2 expression is complex and there are conflicting data in the literature. It has been described that Myc overexpression induces Cdk2 at mRNA and protein level and that silencing of Myc decreases Cdk2 expression in human lung cells [135] . In contrast, Cdk2 expression is not affected by Myc activation in Rat1 cells [136] and no Myc binding to Cdk2 promoter has been described or found by the ENCODE project (ChIP-seq data deposited in the University of California Santa Cruz browser, http://genome.ucsc.edu/). Finally, Myc binding to Cdk1 promoter has been identified by ChIP in mouse embryonic stem cells [107] and in several human cell lines (ChIP-seq data drom ENCODE project in http://genome.ucsc.edu/). Intriguingly, Myc alone is not sufficient to induce the Cdk1 expression [137] and requires cooperation with other proteins as Ras [138] or cyclin C [137] .
Cyclin genes induction.
There is some controversy about cyclin D1 regulation by Myc, and it seems to depend on the cell model. Myc is reported to increase cyclin D1 protein in mouse fibroblasts [139, 140] and rat fibroblasts (Rat1-MycER cells) [139, 141] . On the other hand, it has also been described that MycER activation downregulates cyclin D1 in the same Rat1-MycER cell model [132, 142] . In agreement with the latter result, constitutive expression of Myc also represses cyclin D1 mRNA in BALB/c-3T3 mouse fibroblasts [142, 143] via core promoter elements, antagonizing USFmediated transactivation [143] . In other Rat1-derived cell lines, cyclin D1 expression was not affected by Myc expression [136, 144] .
In contrast to the conflicting data on cyclin D1, it is stablished that cyclin D2 gene (CCND2) is a bona fide Myc target gene. Myc binds to the human cyclin D2 promoter in vivo via a single highly conserved E-box element [145, 146] , induces histone acetylation in a TRRAPdependent manner and induces cyclin D2 mRNA and protein expression [146] . Therefore, Myc promotes G1-phase cell cycle progression in part through the transcriptional up-regulation of the cyclin D2 gene [146] . Myc also increases cyclin D2 protein in mouse fibroblasts [139, 140] . Cyclin D3 can be also considered a Myc target gene as it is upregulated in mouse embryo fibroblasts in response to Myc expression [140] and Myc binds to its promoter (Table1). Moreover, Myc-mediated induction of cyclin D3 has been reported in embryonic lung fibroblasts while Myc silencing downregulates it in lung cancer cells [135] .
Myc also upregulates cyclin E1 and E2 genes (Table 1) . In rat fibroblasts, Myc activation induces cyclin E1 gene transcription and the increase in cyclin E1 mRNA, leading to the activation of cyclin E/Cdk2 complexes and induction of DNA synthesis [131] . Moreover, Myc can induce cyclin E1 expression indirectly through the induction of E2F transcription factors [147] .
Increased cyclin E2 mRNA expression has also been observed in human lung fibroblasts and carcinoma cells overexpressing Myc [135] . Consistently with these findings, Myc binds to cyclin E1 and E2 promoters in human B cells [101] . Cyclin E-type mRNA and protein have also been found upregulated in response to Myc activation in rat fibroblast [132, 136, 142] . In Myctransformed cells separated according to cell size by centrifugal elutriation, cyclin E/Cdk2 kinase activity was upregulated not only in late G1/S, as in the normal counterparts, but throught the entire cell cycle [132] . Taken together the effect of Myc on Cdk4/6, Cdk2, D and Etype cyclins, a picture emerges in which Myc upregulates G1 cyclins/Cdks activity. The importance of this Myc effect is underlined by the observation that the G1 arrest induced by a Myc dominant-negative mutant (MadMyc, section 4) is rescued by ectopic expression of cyclin E/CDK2 and cyclin D1/Cdk4 [83] .
Increased cyclin A mRNA and protein expression is observed in Rat1 fibroblasts with conditional (MycER) or constitutive Myc expression [132, 136, 142, 148, 149] . Furthermore, cyclin A seems to be essential for Myc-dependent progression of cell cycle in human lung fibroblasts and lung carcinoma cells [135] . Myc binding to CCNA2 promoter (but not to CCNA1 promoter) is detected by ChIP-on-ChIP and ChIP-seq in several human cell lines [134] and data from ENCODE project) (Table 1) .
Finally, It has been shown that Myc binds to human cyclin B1 promoter containing a functional Myc binding site in lung cancer cells [150] . Myc binding to cyclin B1 promoter has been confirmed by ChIP in HeLa cells [85] . Moreover it has been described that Myc and loss of p53 cooperate to induce cyclin B1 mRNA and protein in Rat1 cells and 32D myeloid cells stably transfected with a Myc expression vector [151] .
Induction of CAK activity.
In addition to Cdk induction and cyclin binding, the complete activation of cyclin/Cdk complexes requires several phosphorylation and dephosphorylation events at different residues of Cdk proteins. Cyclin/Cdk complexes are activated by CAK (Cdk activating kinase), which phosphorylates the Cdk T loop [152, 153] . Thus, CAK is responsible for the activating phosphorylation of Thr161 in Cdk1, Thr172 in Cdk4 and Thr177 in Cdk6 which are structurally equivalent to Thr160 in Cdk2 [154] . CAK is composed of three subunits: Cdk7 (the catalytic subunit), cyclin H and MAT1. Myc increases CAK activity in rat fibroblasts increasing Cdk7, cyclin H, and MAT1 protein expression through augmented mRNA translation but not by Mycmediated transcriptional activation [155] . Nevertheless, Myc binding to CDK7 promoter has been shown in mouse ES cells [106] (Table 1 ). In agreement, Cdk7 protein expression is reduced in Myc -/-rat cells (HO15.19) [89, 156] . The CAK is also a subunit of TFIIH, one of the general transcription factors present in the RNA polymerase II preinitiation complex [154] . Myc recruits Cdk7 to the transcriptional start site, increases CAK activity and the concomitant phosphorylation on Ser5 of the C-terminal domain (CTD) of RNA polymerase II, a phosphorylation associated to initiation of transcription [155, 157] .
Induction of Cdc25 phosphatases.
Cdks can also be regulated via inhibitory phosphorylations of two conserved residues near the N-terminus (Thr14 and Tyr15 in human Cdk1 and Cdk2) located within the ATP-binding site of the enzyme [153] . Tyr15 phosphorylation is carried out by Wee1 [158] . It has been described that both Myc [159] and N-Myc [160] induce miR-221, which has been shown to target Wee1 [161] . Thus, it is likely that Myc can repress Wee1 by induction of this microRNA, although further studies are required to confirm this hypothesis. miR-221 also affects multiple cancer pathways by modulating other mRNAs, including inhibition of Rb, p27 and p57 [161, 162] . Dephosphorylation of both residues are required for Cdk activation and cell cycle regulation, particularly at mitosis for the control of Cdk1 activation, and this is carried out by dual specific phosphatases of the Cdc25 family [152, 153] . Cdc25A has been proposed to be a Myc target gene [163] 
Myc and p21

CIP1
As mentioned before, Myc represses the cyclin-dependent kinase inhibitor p21
(p21 hereafter). One of the first evidences came from human immortalized keratinocyte cells stably expressing Myc, where Myc inhibited TGFβ-mediated repression of cell-cycle progression abolishing the induction of p21 expression [164] . Several mechanisms are used by Myc to repress p21 and are summarized in Fig. 2A . The most studied mechanism for Myc-mediated repression of p21 is through the initiator-binding transcription factor Miz-1. While Miz-1 stimulates transcription, the direct interaction with Myc transform this zinc-finger transcription factor into a transcriptional repressor [165, 166] . This interaction blocks p21 induction by p53 and, as a consequence, Myc contributes to the initiation of apoptosis by p53 [167] . Moreover, through this mechanism Myc also blocks the p21-mediated differentiation of hematopoietic cells [168] . Furthermore, it has been described that Myc and Miz-1 form a ternary complex with the DNA methyltransferase DMNT3a and that DNA methylation is required for Myc-mediated repression of CDKN1A (p21). This suggest that Myc can silence p21 gene expression not only by passive Miz-1 functional interference but also by active recruitment of corepressor proteins [169] . There are additional mechanisms which allows Myc to repress p21 ( Fig. 2A ): (i) Myc triggers a transcriptional cascade by inducing the gene encoding the transcription factor AP4 (TFAP4), which binds to recognition motifs in the p21 promoter and mediates transcriptional repression of p21 [170] . (ii) Myc antagonized the induction of p21 mediated by oncogenic Ras [171] . p21 upregulation by Ras depends on SP1 and Myc interferes with SP1 transactivation of p21 promoter [171, 172] . (iii) Myc interacts with the histone demethylase KDM5B and with the transcription factor TFAP2C (AP2-gamma) forming a ternary complex that repress p21 transcription [173] . This implies a histone H3 demethylation mechanism for p21 repression. Therefore, both histone demethylation and DNA methylation seems to be required for Mycmediated repression of p21. (iv) Finally, Myc induces the microRNA cluster miR-17-92, which includes miRNAs predicted to target p21 mRNA [159, 174, 175] .
Myc and p27
KIP1
One of the most important targets of Myc in cell proliferation is the Cdk inhibitor p27. Myc accelerates cell proliferation rates, at least in part, through its ability to antagonize p27 activities in proliferation and differentiation [176, 177] . Accordingly, Myc-deficient cells show increased p27 protein levels [89, 91] . This is accomplished by several parallel mechanisms, summarized in Fig. 2B : (i) Myc suppresses p27 expression at transcriptional level in lymphoid and breast cancer cells [178, 179] (Table 1) . (ii) Myc induces de miR-221 and miR-222 that leads to p27 mRNA silencing [159, 162] . Previous experiments have showed that miR-221 is able to induce proliferation targeting p27, both in vitro [162] and in vivo [180] . (iii) Myc induces cyclin E transcription directly or through the induction of E2F transcription factors, increasing the levels of cyclin E/Cdk2 complexes that functionally antagonize p27 by promoting G1/S transition. [130, 131, 176] (iv) Induction of cyclins D1 and D2, as well as their catalytic partners Cdk4 and Cdk6 by Myc, allows the assembly of cyclin D/Cdk4,6 complexes, which sequester p27 and relieve the inhibition of cyclin E/Cdk2 complexes [145, 181, 182] . (v) Myc induces the expression of several components of the SCF SKP2 ubiquitin ligase complex, the major complex that ubiquitinates p27. Thus, Myc induces Cul1 [183] , Cks1 [184] and the F-box protein Skp2, the subunit involved in substrate selection and that recognizes Thr187-phosphorylated p27 [185] . This phosphorylation is required for p27 degradation by the proteasome [186] [187] [188] [189] . Interestingly, Myc also stimulates the Thr187 phosphorylation of p27, likely through the upregulation of Cyclin E/Cdk2 [185, 190] . Since SCF SKP2 is the most important ubiquitin ligase for p27 degradation [191, 192] , Myc appears to be a major regulator of p27 levels in cell nuclei. The general picture describes Myc as a potent inhibitor of p27 activity as cell cycle brake. This is important given that p27 expression is frequently downregulated in human cancer and low p27 levels associate to poor prognosis [193, 194] . However, impairment of p21 and p27 function is not the only pro-proliferative mechanism elicited by Myc, as mouse embryo fibroblasts deficient for both p27 and the related p21 are still responsive to stimulation by Myc and can be arrested in G1 by a dominant negative mutant of Myc [195] .
Myc, DNA replication and mitosis
Myc induces genes directly related to DNA replication. The origin recognition complex (ORC) is a highly conserved six subunits protein complex essential for the initiation of the DNA replication in eukaryotic cells. A number of ORC genes as ORC1, ORC2, ORC4 and ORC5 have been identified as Myc targets in mouse fibroblasts and human B cells [101, 103] . The gene encoding for Cdc6 (Cell Division Cycle 6), a protein required for the initiation of replication, has also been found to be a Myc target gene [101, 108] . Myc also induces genes encoding MCM (minichromosome maintenance) proteins as MCM3, MCM4 and MCM5 [101, 105, 108] , which are essential for correct DNA replication initiation and elongation. Besides the gene expression induction described above, it has been also reported that Myc stimulates DNA replication independently of transcription. The initial observation was the inhibition of the replication of episomal DNA by anti-Myc antibodies [196] . Later on, it was shown that Myc stimulates DNA replication in a transcriptional-independent manner. Myc interacts with the prereplicative complex and localizes to origins of DNA replication in mammalian cells and in Xenopus cell-free extracts. Myc depletion provokes a slow replication due to defective replication initiation once the pre-replicative complexes are assembled [197] . Myc overexpression initiates premature origin firing and increases origin density, and leads to asymmetrical fork progression [197, 198] . Thus, this mechanism explains that, when deregulated, Myc generates DNA replication stress and DNA damage, an observation made in several models [199] [200] [201] [202] . Also, high Myc levels enhance re-replication of DNA in the p21-induced polyploidization process of myeloid cells [203] . However, it is unclear whether this nontranscriptional Myc activity on replication contributes to the DNA replication in the S-phase of cells with physiological Myc levels. Last but not least, Myc activates the transcription of human telomerase (TERT), which may contribute to sustain the proliferation of tumor cells along the cell cycle [204, 205] .
Finally, not only Cdk1 and mitotic cyclins, but some genes encoding proteins required for mitosis are also regulated by Myc. The anaphase promoting complex/cyclosome (APC/C) is a multisubunit E3 ubiquitin ligase required for mitotic progression by targeting for destruction key mitotic regulators such as cyclin B1 and securin, the separase inhibitor required for the correct anaphase [206, 207] . Myc induce the genes encoding three subunits of APC/C: Anapc5, Cdc16 and Cdc23 [103] and binds their promoter in mouse embryonic stem (ES) cells and human myeloid cells ( [107] and ENCODE project, http://genome.ucsc.edu/). Myc would not only promote securin degradation through upregulation of APC/C sununits but also repress the securin gene (Pttg1) [103] , suggesting a major role in mitotic control. On the other hand, it has also been reported that Myc represses Anapc2 (another component of the APC/C complex) and Cdc20, the APC/C coactivator [103] . Moreover, Myc also activates the expression of human BubR1 and Mad2 genes, two APC/C repressors, delaying prometaphase [208] . The effects of Myc on mitotic progression are not well understood yet, although the Myc-mediated induction of some of these regulators (e.g, BubR1 and Mad2) has been related to the chromosomal instability elicited by deregulated Myc [208] [209] [210] 
Conclusion and remarks
We have reviewed here the many functions of Myc related to the cell cycle regulation. From the pioneering studies in the 1980's to the genome-wide studies today, the general picture shows that control of cell proliferation is one of the major roles of Myc in cell biology. The bulk of data shows that Myc overexpression stimulates whereas Myc downregulation inhibits cell cycle progression. Several mechanisms by which Myc influences the cell cycle have been elucidated. Most of them are related to the Myc-mediated induction or repression of target genes encoding positive or negative cell cycle regulators, respectively. However, there are still many unclear aspects of these mechanisms. The stimulation of cell cycle progression is likely the most relevant activity -albeit not the only one -for the oncogenic activity of Myc. Given the frequent deregulation of Myc oncogene observed in many human tumours it is of crucial importance to further decipher the molecular mechanisms underlying the role of Myc on the regulation of the cell cycle. Although Myc is not an easily druggable target, a promising approach to deal with tumors with deregulated Myc is the synthetic lethality based on the inhibition of Cdks. In this line, it has been described synthetic-lethal interaction between Myc and Cdk1 in lymphoma, liver cancer and breast cancer [211, 212] . The effort to elucidate the Myc-dependent cell cycle regulatory mechanisms would eventually help to discover new therapeutic approaches directed against malignancies with deregulated Myc. Table 1 . Myc target genes involved in cell cycle. ChIP, chromatin immunoprecipitation; ChIP-onchip, ChIP followed by analysis by chip microarray of the immunoprecipitated chromatin/DNA; ChIP-seq, ChIP followed by sequencing of the immunoprecipitated chromatin/DNA ChIP-PET, ChiP coupled with pair-ends tag sequencing. Human gene nomenclatura is used. 
